JP2024511973A - Ｃｎｓ疾患および全身性疾患を治療するためのｌｉｎｅ－１阻害剤 - Google Patents

Ｃｎｓ疾患および全身性疾患を治療するためのｌｉｎｅ－１阻害剤 Download PDF

Info

Publication number
JP2024511973A
JP2024511973A JP2023556734A JP2023556734A JP2024511973A JP 2024511973 A JP2024511973 A JP 2024511973A JP 2023556734 A JP2023556734 A JP 2023556734A JP 2023556734 A JP2023556734 A JP 2023556734A JP 2024511973 A JP2024511973 A JP 2024511973A
Authority
JP
Japan
Prior art keywords
line
inhibitor
disease
subject
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511973A5 (https=
Inventor
エッカルト ウェーバー
マイケル ジー． コーディングリー
Original Assignee
トランスポゾン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランスポゾン セラピューティクス インコーポレイテッド filed Critical トランスポゾン セラピューティクス インコーポレイテッド
Publication of JP2024511973A publication Critical patent/JP2024511973A/ja
Publication of JP2024511973A5 publication Critical patent/JP2024511973A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
JP2023556734A 2021-03-15 2022-03-15 Ｃｎｓ疾患および全身性疾患を治療するためのｌｉｎｅ－１阻害剤 Pending JP2024511973A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163161050P 2021-03-15 2021-03-15
US63/161,050 2021-03-15
PCT/US2022/020362 WO2022197689A1 (en) 2021-03-15 2022-03-15 Line-1 inhibitors to treat cns and systemic diseases

Publications (2)

Publication Number Publication Date
JP2024511973A true JP2024511973A (ja) 2024-03-18
JP2024511973A5 JP2024511973A5 (https=) 2025-03-25

Family

ID=83321069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556734A Pending JP2024511973A (ja) 2021-03-15 2022-03-15 Ｃｎｓ疾患および全身性疾患を治療するためのｌｉｎｅ－１阻害剤

Country Status (15)

Country Link
US (1) US20240173346A1 (https=)
EP (1) EP4308237A4 (https=)
JP (1) JP2024511973A (https=)
KR (1) KR20230157430A (https=)
CN (1) CN117355312A (https=)
AU (1) AU2022237405A1 (https=)
BR (1) BR112023018714A2 (https=)
CA (1) CA3211369A1 (https=)
CL (1) CL2023002746A1 (https=)
DO (1) DOP2023000192A (https=)
IL (1) IL305869A (https=)
MA (1) MA62910A1 (https=)
MX (1) MX2023010657A (https=)
UA (1) UA130707C2 (https=)
WO (1) WO2022197689A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
WO2021102423A1 (en) 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US20250170158A1 (en) * 2022-02-22 2025-05-29 Rome Therapeutics, Inc. Methods of treating medical conditions using censavudine or a related compound
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease
WO2023178128A1 (en) * 2022-03-15 2023-09-21 Rome Therapeutics, Inc. Methods of treating medical conditions using islatravir or a related compound
CA3246792A1 (en) * 2022-03-30 2023-10-05 Transposon Therapeutics, Inc. NUCLEOSIDE LINE-1 INHIBITORS
WO2024129788A1 (en) * 2022-12-13 2024-06-20 Brown University Small molecule inhibitors of the line-1 endonuclease domain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2535045T3 (es) * 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Usos y composiciones para administración de capsaicina
EP2965760A1 (en) * 2014-07-09 2016-01-13 Université de Montpellier Combination of antiretroviral agents for use in the prevention or treatment of chronic inflammatory diseases
CN105012305A (zh) * 2015-07-24 2015-11-04 福建广生堂药业股份有限公司 拉米夫定及其药用盐治疗老年性黄斑部病变的用途
RU2726210C2 (ru) * 2018-12-27 2020-07-09 Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" Комбинация противовирусных средств, набор и способ лечения на ее основе
EP3914604B1 (en) * 2019-01-25 2026-03-04 Brown University Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders
TW202104210A (zh) * 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑

Also Published As

Publication number Publication date
AU2022237405A1 (en) 2023-11-02
UA130707C2 (uk) 2026-04-22
WO2022197689A1 (en) 2022-09-22
KR20230157430A (ko) 2023-11-16
MA62910A1 (fr) 2023-12-29
EP4308237A1 (en) 2024-01-24
DOP2023000192A (es) 2024-02-29
CL2023002746A1 (es) 2024-04-05
EP4308237A4 (en) 2025-03-05
US20240173346A1 (en) 2024-05-30
CN117355312A (zh) 2024-01-05
MX2023010657A (es) 2023-09-21
BR112023018714A2 (pt) 2023-10-24
IL305869A (en) 2023-11-01
CA3211369A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
JP2024511973A (ja) Ｃｎｓ疾患および全身性疾患を治療するためのｌｉｎｅ－１阻害剤
TWI687415B (zh) Hiv蛋白質膜抑制劑之固體形式
ES2688925T3 (es) Tratamiento antiviral
JP2023011754A (ja) Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
JP4629104B2 (ja) ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤
ES2660263T5 (en) Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
CA2450777C (en) Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
JPH10511682A (ja) ジドブジン、１５９２ｕ８９および３ｔｃまたはｆｔｃの相乗的組み合わせ
ES2797900T3 (es) Compuestos y combinaciones para el tratamiento del VIH
JP2018532784A (ja) 低増殖性障害の治療のための化合物
JP2024520132A (ja) 向知性薬としてのｌｉｎｅ－１阻害剤
AU2016308704B2 (en) MDM2 inhibitors for treating uveal melanoma
US20200323851A1 (en) Alk5 inhibitors for treating myelodysplastic syndrome
EP1113802B1 (en) Antiviral combinations of lamivudine and adefovir
JP2002534390A (ja) 癌治療におけるアデノシンアゴニスト類の使用
US20220016118A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
TW201736391A (zh) 作為人類鼻病毒抑制劑之炔基核苷類似物
US20210000802A1 (en) Pharmaceutical composition for preventing or treating aids comprising rhodanine derivative
OA21831A (en) LINE-1 inhibitors to treat CNS and systemic diseases.
JP2002540149A (ja) ウイルス感染治療のためのカルバミン酸エステル誘導体の使用法
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
ITMI20131218A1 (it) Nuovi ureido derivati di acidi naftalensolfonici
US20150104416A1 (en) Leukemic Stem Cell Ablation
KR20070114806A (ko) 바이러스 감염 치료에의 티오포스포노포름산 및 ｎｒｔｉ의용도
HK1035670B (en) Antiviral combinations of lamivudine and adefovir

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314